CG-211

CG-211 is an investigational adeno-associated virus (AAV)-based gene therapy designed for the treatment of retinal vascular diseases, specifically neovascular (wet) age-related macular degeneration (wAMD) and diabetic macular edema (DME). Developed by CureGene, the therapy utilizes a viral vector to deliver a genetic payload into retinal cells, enabling the continuous endogenous production of a protein that antagonizes vascular endothelial growth factor (VEGF). By inhibiting VEGF signaling, CG-211 aims to suppress the abnormal blood vessel growth and vascular permeability that characterize these conditions, potentially offering a long-term alternative to frequent intravitreal injections of recombinant anti-VEGF proteins. The program is currently undergoing Phase 1 clinical evaluation to assess safety, tolerability, and preliminary efficacy.